Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusWill there ever be a universal Staphylococcus aureus vaccine?Where does a Staphylococcus aureus vaccine stand?Iron and zinc exploitation during bacterial pathogenesisDesign of live attenuated bacterial vaccines based on D-glutamate auxotrophy.Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye.IL-23 p19 knockout mice exhibit minimal defects in responses to primary and secondary infection with Francisella tularensis LVSNeutrophil-derived IL-1β is sufficient for abscess formation in immunity against Staphylococcus aureus in miceAntibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolatesEvaluation of genetically inactivated alpha toxin for protection in multiple mouse models of Staphylococcus aureus infection.Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Evaluation of the protective immunity of a novel subunit fusion vaccine in a murine model of systemic MRSA infection.Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in miceA Multiple Antigenic Peptide Mimicking Peptidoglycan Induced T Cell Responses to Protect Mice from Systemic Infection with Staphylococcus aureus.Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A.MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers.Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia modelsThe T Cell Response to Staphylococcus aureusEpicutaneous model of community-acquired Staphylococcus aureus skin infections.Clearance of Staphylococcus aureus nasal carriage is T cell dependent and mediated through interleukin-17A expression and neutrophil influxNovel synthetic (poly)glycerolphosphate-based antistaphylococcal conjugate vaccine.The roles of transition metals in the physiology and pathogenesis of Streptococcus pneumoniaeNaturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans.Efficacy of Antibody to PNAG Against Keratitis Caused by Fungal Pathogens.Biofilm matrix exoproteins induce a protective immune response against Staphylococcus aureus biofilm infection.Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A.Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli.Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations.Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.Phagocyte subsets and lymphocyte clonal deletion behind ineffective immune response to Staphylococcus aureus.Deciphering the significance of the T-cell response to Staphylococcus aureus.Lethal CD4 T Cell Responses Induced by Vaccination Against Staphylococcus aureus Bacteremia.Adaptive Immunity Against Staphylococcus aureus.Staphylococcus aureus Protein A Disrupts Immunity Mediated by Long-Lived Plasma Cells.Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.The Fall of a Dogma? Unexpected High T-Cell Memory Response to Staphylococcus aureus in Humans.Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors.
P2860
Q26780246-6177BEDC-7694-43AB-B029-6E249489E3ADQ26824837-2AF705E7-3957-4FF4-8359-330613331831Q26828726-79FCB8AB-39C4-4974-A29F-7ED6AFABC7F3Q28082191-3B7993C9-DB68-4D24-839D-10BF5CE8CA9FQ33763029-58A67835-F8E5-40C6-8EEA-43B2C2AD6E5FQ34059043-26D2465C-8859-454A-A91F-27D5892AE143Q34309279-E27669B2-311F-4BC1-A421-E1D01986C4DDQ34499405-48E9BA47-694E-45D3-B4BC-074678CEDE5DQ34595644-B4035E86-9182-41D1-BA4C-3F25992F69DDQ34712265-3B2BEC02-09E4-483C-BE0F-2ABEB968C96BQ34792962-212FADE5-C6B2-4E93-B043-321E1A7DA4DFQ35063930-1AB15078-FA13-45EE-A64C-E7FCFF700661Q35116935-2FD2B087-2BB5-4281-B886-C58AF8A6123CQ35758457-CADA87AB-8B07-4025-90CF-8D637396732EQ35833250-4F6E8ED0-8FC6-43E7-9835-10A9D8CBFF8BQ35904895-EAC712E4-D77E-494F-883F-8808E404127EQ36032570-DAB3F0B8-5CD4-4B1D-A32F-251620478653Q36569841-E17CADA9-2AD0-48BC-A7E0-895B64BA1B38Q36735452-2E625908-645A-45D7-8779-E9F14C98C33EQ36804704-5B7879B6-7B3D-4F72-B70A-162F0BF48136Q36911421-949578B3-C6CE-4800-B9B3-33929DB40B4BQ36970896-F36647C1-32BC-49FA-8B7D-EE80AF974228Q37361695-1F2371EE-AA89-402C-8A3F-2995B66BAD4FQ37530311-6F702C86-C492-49A9-A03C-B9C2D216786BQ37561334-5D0C84AF-2EB0-4473-AF11-F8FEBBBE92FCQ37643833-5987CAD6-D54D-464C-A42C-F4F103BDE311Q37713405-E38FD6AA-E128-4ADC-9FE4-0B482EC0C5F8Q37719754-7E67726C-3946-4D6D-81AF-79706E310CA7Q38038043-54FFDA83-CE3C-4FC8-BB39-EC0A03B5BC9EQ38168915-F4203397-9E68-4A6B-AB76-14CBE9465D15Q38177271-10B93CE1-6905-43CF-A09B-61662D5C6802Q38494482-773C0CAC-451E-4B6C-81CC-5931034E61ECQ38651177-FABDA9A8-1285-45E6-B42B-DE3C2399F7A6Q38741540-C7ADE54E-A9F9-4168-B0F1-38D014C38A33Q38751767-6310D5E6-6FD7-4529-AE6A-E3ED7F2D28F7Q40392346-07A3054B-493F-4996-9923-A8DDAFA78136Q40416064-68E97B60-961A-45A6-AF24-DBD5173D4E15Q40697398-40770302-F781-4656-AA2A-3EB6B6189526Q41451687-3A505C7E-2A75-4A18-85EE-E012F4F8B172Q41611973-4B20FC06-8761-4026-8E01-D850C9A11535
P2860
Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunization with Staphylococc ...... thway in a murine sepsis model
@ast
Immunization with Staphylococc ...... thway in a murine sepsis model
@en
type
label
Immunization with Staphylococc ...... thway in a murine sepsis model
@ast
Immunization with Staphylococc ...... thway in a murine sepsis model
@en
prefLabel
Immunization with Staphylococc ...... thway in a murine sepsis model
@ast
Immunization with Staphylococc ...... thway in a murine sepsis model
@en
P2093
P2860
P356
P1476
Immunization with Staphylococc ...... thway in a murine sepsis model
@en
P2093
Amita Joshi
Daniel Cua
Edward P Bowman
Greg Pancari
Leslie Cope
Richard A Proctor
Tessie McNeely
P2860
P304
P356
10.4161/HV.18946
P577
2012-02-13T00:00:00Z